Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of Fleximer conjugates for oncology, today announced its participation in the upcoming 2014 World ADC Summit taking place October 26-29, 2014, at the Marriott Marquis in San Diego.

Timothy B. Lowinger, Ph.D., Chief Scientific Officer, will present “Fleximer-based Next Generation ADCs: Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index,” in the Discovery Stream on Tuesday, October 28, 2014, at 10:30 a.m. PDT.

About Mersana

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Mersana is developing, with select pharmaceutical partners, a portfolio of next-generation Fleximer-ADCs with superior properties not achievable with direct conjugation ADC technologies. The company is also advancing its own pipeline of Fleximer-ADCs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications.

Media Contacts

 MacDougall Biomedical Communications
 Kari Watson or Charles Liles
 kwatson@macbiocom.com or cliles@macbiocom.com
 +1 781 235 3060